2020
NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020.
Becker PS, Griffiths EA, Alwan LM, Bachiashvili K, Brown A, Cool R, Curtin P, Dinner S, Gojo I, Hicks A, Kallam A, Kidwai WZ, Kloth DD, Kraut EH, Landsburg D, Lyman GH, Miller R, Mukherjee S, Patel S, Perez LE, Poust A, Rampal R, Rosovsky R, Roy V, Rugo HS, Shayani S, Vasu S, Wadleigh M, Westbrook K, Westervelt P, Burns J, Keller J, Pluchino LA. NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020. Journal Of The National Comprehensive Cancer Network 2020, 18: 12-22. PMID: 31910384, DOI: 10.6004/jnccn.2020.0002.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsBiosimilar PharmaceuticalsChemotherapy-Induced Febrile NeutropeniaDrug ApprovalDrug CostsEducation, Medical, ContinuingHematopoietic Cell Growth FactorsHumansMedical OncologyNeoplasmsOncologistsOrganizations, NonprofitPractice Guidelines as TopicRisk FactorsUnited StatesUnited States Food and Drug AdministrationConceptsFebrile neutropeniaNCCN guidelinesHematopoietic growth factorsGrowth factorManagement of FNTreatment of FNSelect patientsSupportive careNonmyeloid malignanciesCancer treatmentAppropriate evaluationAppropriate usePatientsRisk determinationTreatmentImportant updatesGuidelinesNeutropeniaProphylaxisMalignancyCliniciansFactorsCarePrevention
2018
NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018.
Shah MH, Goldner WS, Halfdanarson TR, Bergsland E, Berlin JD, Halperin D, Chan J, Kulke MH, Benson AB, Blaszkowsky LS, Eads J, Engstrom PF, Fanta P, Giordano T, He J, Heslin MJ, Kalemkerian GP, Kandeel F, Khan SA, Kidwai WZ, Kunz PL, Kuvshinoff BW, Lieu C, Pillarisetty VG, Saltz L, Sosa JA, Strosberg JR, Sussman CA, Trikalinos NA, Uboha NA, Whisenant J, Wong T, Yao JC, Burns JL, Ogba N, Zuccarino-Catania G. NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018. Journal Of The National Comprehensive Cancer Network 2018, 16: 693-702. PMID: 29891520, DOI: 10.6004/jnccn.2018.0056.Peer-Reviewed Original ResearchConceptsPrimary neuroendocrine tumorNeuroendocrine tumorsAdrenal tumorsManagement of NETsLocoregional advanced diseaseNCCN Guidelines InsightsAdrenal gland tumorsAdvanced diseaseNCCN guidelinesAdult patientsDistant metastasisGastrointestinal tractGland tumorsTumorsNeuroendocrineManagement optionsGuidelinesPatientsPheochromocytomaMetastasisParagangliomaDiseaseTract